|
|
|
1-10 employees
View all
|
|
Biotechnology
|
|
London, GB
|
|
Complement Therapeutics (CTx) is an early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade.
Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for dry age-related macular degeneration/geographic atrophy, a leading cause of blindness. Additional programmes will evaluate potential therapeutic opportunities in other complement-mediated conditions.
The Company is also developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform, to enable quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease.
|
Complement Therapeutics Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Complement Therapeutics email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Complement Therapeutics customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.